与SGLT2i使用相关的血糖正常性糖尿病酮症酸中毒:病例系列
该病例系列纳入5例在大型三级医院急诊科诊断的血糖正常性糖尿病酮症酸中毒(EuDKA)且使用SGLT2i的成人患者,中位年龄57岁,表现为恶心、呕吐、乏力和意识改变。初始血糖191 mg/dL、静脉pH 7.01、HCO3 8 mEq/L、阴离子间隙27、β-羟丁酸9.9 mmol/L、尿酮体150。胰岛素输注中位18.77小时,零次低血糖、一次低钾血症,代谢性酸中毒缓解时间23.82小时。作者认为急诊医生应认识SGLT2i与EuDKA的关联。
要点
- 服用SGLT2i的成人出现恶心、呕吐、乏力或意识改变时,即使血糖不高(中位191 mg/dL),也需排查EuDKA。
- 不明原因的高阴离子间隙代谢性酸中毒(中位阴离子间隙27)应促使急诊医生追问SGLT2i用药史。
- 本系列5例患者胰岛素输注中位18.77小时,期间零次低血糖、一次低钾血症。
- 代谢性酸中毒缓解中位时间23.82小时,提示需持续监测酸中毒和电解质。
适用人群与场景
- 急诊科就诊的成人患者,表现为恶心、呕吐、乏力、意识改变,或不明原因的高阴离子间隙代谢性酸中毒,且正在使用SGLT2i。
诊断标准与关键阈值
- 血糖正常性糖尿病酮症酸中毒(EuDKA):本系列患者初始血清葡萄糖中位191 mg/dL(范围176-215),静脉pH中位7.01(范围6.95-7.30),血清HCO3中位8 mEq/L(范围6-13),阴离子间隙中位27(范围26-31),血清β-羟丁酸中位9.9 mmol/L(范围9.2-12.3),尿酮体中位150(范围150-150)。
处置流程与药物剂量
- 本系列患者接受胰岛素输注,中位持续时间18.77小时(范围11.25-56.48小时)。
红旗征与不能漏的情况
- 服用SGLT2i者出现恶心、呕吐、乏力、意识改变,或不明原因的高阴离子间隙代谢性酸中毒,需警惕EuDKA。
研究设计与关键结果
- 病例系列纳入5例成人患者,中位年龄57岁(范围43-73岁),表现为恶心、呕吐、乏力和意识改变;初始血清葡萄糖中位191 mg/dL(范围176-215),静脉pH中位7.01(范围6.95-7.30),血清HCO3中位8 mEq/L(范围6-13),阴离子间隙中位27(范围26-31),血清β-羟丁酸中位9.9 mmol/L(范围9.2-12.3),尿酮体中位150(范围150-150)。
- 胰岛素输注中位持续时间18.77小时(范围11.25-56.48小时),期间零次低血糖发作、一次低钾血症发作。
- 代谢性酸中毒缓解中位时间23.82小时(范围15.45-24.77小时)。
证据类型、等级与局限
- 证据类型:病例系列(5例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急诊医生应认识SGLT2i使用与EuDKA之间的关联。
- 作者认为,对服用SGLT2i且出现提示DKA症状(包括恶心、呕吐、不适和意识改变)或发现不明原因的高阴离子间隙代谢性酸中毒的患者,应进行适当的检查。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Euglycemic diabetic ketoacidosis (EuDKA) associated with Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) use has been described but remains poorly understood. Data on Emergency Department (ED) presentation, resource utilization, and safety outcomes for these patients are lacking. We report a case series of patients diagnosed with EuDKA in the ED.
METHODS: An electronic medical record search identified adult patients presenting to a large tertiary ED with EuDKA. They were screened for concurrent use of SGLT2i. Clinical presentation, resource utilization, safety, and disposition data were collected and described.
RESULTS: Five patients were included for analysis. Median age [range] was 57 [43-73] years. Presenting symptoms included nausea, vomiting, fatigue, and altered mental status. Initial results included: serum glucose 191 mg/dL [176-215], venous pH 7.01 [6.95-7.30], serum HCO3 8 mEq/L [6-13], anion gap 27 [26-31], serum beta-hydroxybutyrate 9.9 mmol/L [9.2-12.3], and urine ketones 150 [150-150]. Patients remained on an insulin infusion for 18.77 h [11.25-56.48]. There were zero episodes of hypoglycemia and one episode of hypokalemia while on insulin infusion. Time to resolution of metabolic acidosis was 23.82 h [15.45-24.77].
DISCUSSION: We report a case series of ED patients with EuDKA associated with SGLT2i use, and describe presentation characteristics, resource utilization, and safety outcomes. Emergency physicians should be aware of the association between SGLT2i use and EuDKA. An appropriate work-up should be pursued for patients taking an SGLT2i who present with symptoms suggestive of DKA, including nausea, vomiting, malaise, and altered mental status, or are noted to have an unexplained elevated anion gap metabolic acidosis.
参考来源
- Puls HA, Haas NL, Franklin BJ, et al. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series. Am J Emerg Med. 2021. PMID: 33571749. doi:10.1016/j.ajem.2021.01.033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。